Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Blood Test Could Diagnose Brain Cancer, Track Progression and Guide Treatment

By LabMedica International staff writers
Posted on 28 Feb 2023

Glioblastoma (GBM) is a particularly aggressive type of brain cancer with a five-year survival rate of only 5%. More...

Researchers have now identified a biomarker that could be used in blood tests to diagnose GBM, track its progression and guide treatment. This means non-invasive liquid biopsy for GBM could be a great help for patients, allowing them to receive the care they need more quickly. Such a liquid biopsy test could potentially have enormous value in treating GBM.

Researchers at Penn State College of Medicine (Hershey, PA, USA) studied an antigen receptor, called interleukin-13 receptor α2 (IL13Rα2), which increases in the tumor tissue of over 75% of GBM patients. The team examined the utility of IL13Rα2 as a biomarker for GBM by analyzing the tumor tissue and blood plasma of 79 patients with primary GBM, along with the blood plasma of 23 control patients, from two separate health systems. The control patients had been primarily diagnosed with either spinal stenosis or arteriovenous malformation but did not suffer from any malignancy or chronic inflammation.

In the patients’ plasma, the team specifically examined extracellular vesicles, which are small particles released by cells and carry material from those cells. The researchers found that GBM patients had significantly high IL13Rα2 levels in their blood plasma as compared to control patients and that the IL13Rα2 was mostly concentrated on extracellular vesicles derived from tumor cells. It was also found that these IL13Rα2 levels in blood plasma were correlated with the IL13Rα2 levels in the patients’ tumors.

The finding is significant as IL13Rα2 has been demonstrated to have a patchy distribution in GBM tumors, raising doubts over whether a needle biopsy or small sample of tumor tissue is representative of the tumor as a whole. In addition, the researchers found that elevated levels of IL13Rα2 in both plasma and tumors were a predictor of longer overall survival. In fact, patients with high levels of plasma IL13Rα2 had a 6.5 month longer median overall survival as compared to patients with low levels.

“Patients normally receive imaging, such as MRI or CT scans, to diagnose and track the progression of brain tumors, but it can be difficult for physicians to tell from those scans if the patient is getting better or worse because they don’t provide detail at the cellular or molecular level,” said Vladimir Khristov, graduate and medical student, Penn State. “That is why we need a supplemental diagnostic test to help physicians determine if the tumors are responding to therapy and regressing, or if they are getting worse and need additional treatment.”

“A liquid biopsy may facilitate diagnosis and more importantly provide a better understanding of the tumor’s response to treatment in a way that is lacking with our current technologies,” added Brad Zacharia, associate professor of neurosurgery and of otolaryngology, Penn State.

Related Links:
Penn State College of Medicine 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Platelet Function Analyzer
PL-12
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.